Is the risk of tenofovir-induced nephrotoxicity similar in treatment-naïve compared to treatment-experienced patients?

Is the risk of tenofovir-induced nephrotoxicity similar in treatment-naïve compared to treatment-experienced patients?

Background: Tenofovir disoproxil fumarate (TDF) is the recommended first-line nucleoside reverse transcriptase inhibitor (NRTI) in the management of human immunodeficiency virus (HIV); however, its use is associated with nephrotoxicity. Aim: To assess if the risks of renal impairment were similar in...

Full description

Bibliographic Details
Main Authors:	Low, Joo Zheng, Khoo, Su Pei, Nor Azmi, Nuruljannah, Chong, Meng Li, Sulaiman, Helmi, Azwa, Iskandar, Tan, Ching Hooi, Kamarulzaman, Adeeba, Rajasuriar, Reena
Format:	Article
Published:	Wiley 2018
Subjects:	R Medicine

Similar Items

Tenofovir Nephrotoxicity: 2011 Update
by: Beatriz Fernandez-Fernandez, et al.
Published: (2011-01-01)

Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B: Detailed Analysis of Treatment-Naive and Experienced Patients
by: Yu-Xuan Song, et al.
Published: (2025-01-01)

Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve and treatment-experienced people with HIV: 12-month virologic effectiveness and safety outcomes in the BICSTaR Japan cohort
by: Yoshiyuki Yokomaku, et al.
Published: (2025-01-01)

Lipid safety of tenofovir alafenamide during 96-week treatment in treatment-naive chronic hepatitis B patients
by: Wenjuan Zhao, et al.
Published: (2024-06-01)

Noninferiority Outcomes of Besifovir Compared to Tenofovir Alafenamide in Treatment-Naïve Patients with Chronic Hepatitis B
by: Tae Hyung Kim, et al.
Published: (2024-03-01)

HIV model incorporating differential progression for treatment-naive and treatment-experienced infectives
by: Esther Chigidi, et al.
Published: (2009-05-01)

Mitotherapy inhibits against tenofovir induced nephrotoxicity on rat renal proximal tubular cells
by: Mir-Jamal Hosseini, et al.
Published: (2024-07-01)

Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced
by: Hyun Woong Lee, et al.
Published: (2017-09-01)

Prognostic model for nephrotoxicity among HIV-positive Zambian adults receiving tenofovir disoproxil fumarate-based antiretroviral therapy.
by: Freeman W Chabala, et al.
Published: (2021-01-01)

Antiviral Efficacy and Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate in the Treatment of Chronic Hepatitis B
by: Tuvshinbayar Narangerel, et al.
Published: (2020-12-01)

Treatment Management Challenges in Naïve and Experienced HIV-1-Infected Individuals Carrying the M184V Mutation
by: Iordanis Mimtsoudis, et al.
Published: (2024-08-01)

Effect of platelet activating factor antagonist treatment on gentamicin nephrotoxicity
by: A. Rodriguez-Barbero, et al.
Published: (1992-01-01)

Reversion by ozone treatment of acute nephrotoxicity induced by cisplatin in rats
by: Ricardo González, et al.
Published: (2004-01-01)

Significant loss of retinal nerve fibre layer and contrast sensitivity in people with well controlled HIV disease: implications for aging with HIV
by: Malinee Neelamegam, et al.
Published: (2023-12-01)

NEPHROTOXICITY ATTRIBUTED TO MEGLUMINE ANTIMONIATE (GLUCANTIME) IN THE TREATMENT OF GENERALIZED CUTANEOUS LEISHMANIASIS
by: M.L.O. RODRIGUES, et al.
Published: (1999-01-01)

Tenofovir and Doravirine Are Potential Reverse-Transcriptase Analogs in Combination with the New Reverse-Transcriptase Translocation Inhibitor (Islatravir) Among Treatment-Experienced Patients in Cameroon: Designing Future Treatment Strategies for Low- and Middle-Income Countries
by: Alex Durand Nka, et al.
Published: (2025-01-01)

Cost–utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B
by: Dakin, H, et al.
Published: (2011)

Acquired Fanconi Syndrome from Tenofovir Treatment in a Patient with Hepatitis B
by: Shirley X. Jiang, et al.
Published: (2023-01-01)

Synthesis and characterization of tenofovir disoproxil fumarate loaded nanoparticles for HIV‐1 treatment
by: Oluwafemi Samuel Obisesan, et al.
Published: (2024-06-01)

Nephrotoxicity of HAART
by: Robert Kalyesubula, et al.
Published: (2011-01-01)

Global, regional, and national prevalence of HIV-1 drug resistance in treatment-naive and treatment-experienced children and adolescents: a systematic review and meta-analysisResearch in context
by: Lingyun Ge, et al.
Published: (2024-11-01)

Quality of Life in Yoga Experienced and Yoga Naïve Asian Indian Adults with Obesity
by: Shirley Telles, et al.
Published: (2019-01-01)

Assessment of risk factors for virological nonsuppression following switch to dolutegravir and lamivudine, or bictegravir, emtricitabine, and tenofovir alafenamide fumarate in a real-world cohort of treatment-experienced adults living with HIV.
by: Shu-Yuan Lee, et al.
Published: (2024-01-01)

Optimization in the HIV treatment: economic and organizational impact analysis of Bictegravir/Emtricitabine/Tenofovir Alafenamide
by: Lucrezia Ferrario, et al.
Published: (2025-02-01)

Two’s a Company, Three’s a Crowd: A Review of Initiating or Switching to a Two-Drug Antiretroviral Regimen in Treatment-Naïve and Treatment-Experienced Patients Living with HIV-1
by: Melissa Badowski, et al.
Published: (2020-03-01)

Editorial: Pathogenic mechanisms, injury biomarkers, prophylaxis and treatment strategy of drug-induced nephrotoxicity
by: Guozheng Jiao, et al.
Published: (2024-04-01)

Comparison of hepatocellular carcinoma incidence after long-term treatment with besifovir vs. tenofovir AF
by: Hyuk Kim, et al.
Published: (2025-02-01)

Effectiveness of tenofovir/emtricitabine versus zidovudine/lamivudine in combination with efavirenz in antiretro viral-naive HIV infected patients / Siti Mahanim Shaik Ismail
by: Shaik Ismail, Siti Mahanim
Published: (2015)

Endoscopic Treatment of Zenker’s Diverticulum: Comparable Treatment Outcomes in Treatment-Naïve and Pretreated Patients
by: Johannes Manzeneder, et al.
Published: (2021-01-01)

Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial
by: Anna Maria Geretti, et al.
Published: (2015-01-01)

Prospective, multicentre, randomised controlled trial comparing the seroclearance of HBsAg between combination therapy of peg-interferon alpha and tenofovir with tenofovir monotherapy in nucleos(t)ide analogue-experienced patients with HBV-related liver fibrosis: a study protocol
by: Jianguo Li, et al.
Published: (2021-10-01)

Recycling tenofovir in second-line antiretroviral treatment with dolutegravir: outcomes and viral load trajectories to 72 weeks
by: Keene, CM, et al.
Published: (2023)

Response of treatment-naive brain metastases to stereotactic radiosurgery
by: Chibawanye I. Ene, et al.
Published: (2024-05-01)

Reply to correspondence on “Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide”
by: Pin-Nan Cheng, et al.
Published: (2024-10-01)

Comparison of lipid profile alterations in chronic hepatitis b patients receiving tenofovir alafenamide or tenofovir disoproxil fumarate
by: Shenglong Lin, et al.
Published: (2024-11-01)

Accurate route demonstration by experienced homing pigeons does not improve subsequent homing performance in naive conspecifics.
by: Banks, A, et al.
Published: (2000)

HBsAg kinetics after 7 years of therapy with tenofovir disoproxil fumarate in a cohort of naïve patients affected by chronic hepatitis B with different genotypes
by: Lucio Boglione, et al.
Published: (2024-03-01)

Enrichment of gut-derived Fusobacterium is associated with suboptimal immune recovery in HIV-infected individuals
by: Lee, Soo Ching, et al.
Published: (2018)

Adipocyte mitochondrial gene expression following 18-24 months treatment with zidovidine or tenofovir-containing antiretroviral therapy
by: McGee, K, et al.
Published: (2009)

Acyclovir Nephrotoxicity: A Case Report Highlighting the Importance of Prevention, Detection, and Treatment of Acyclovir-Induced Nephropathy
by: Raymond Fleischer, et al.
Published: (2010-01-01)